Premium
Pretreatment serum β 2 ‐microglobulin in multiple myeloma
Author(s) -
Brenning Gunilla,
Simonsson Bengt,
Källander Claes,
Åhre Anders
Publication year - 1986
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1986.tb02903.x
Subject(s) - creatinine , beta 2 microglobulin , multiple myeloma , medicine , gastroenterology , renal function , urology
S ummary . Serum beta 2 ‐microglobuline (S‐β 2 m) was evaluated in 121 untreated patients with multiple myeloma. Values > 3 mg/l were found in 82% of the patients. Mean S‐β 2 m values of the total group of patients correlated with clinical stage. However, there was no correlation if values were corrected for S‐creatinine. Seventy‐nine patients had normal (106 μmol/l) and 52 patients abnormal S‐creatinine. Patients with S‐β 2 m values below 7·6 mg/l had an estimated median survival of 44 months compared to 12 months for patients with levels above 7·6 mg/l. If S‐β 2 m values in patients with normal S‐creatinine were combined with values corrected for S‐creatinine from patients with elevated S‐creatinine a β 2 m cut off level of 6·6 mg/l gave a median probable survival of 43 months compared to 14 months. We conclude that pretreatment S‐β 2 microglobulin is a useful marker for predicting survival in multiple myeloma. The problem of the relationship between S‐β 2 m and S‐creatinine is discussed.